Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline).

No abstract is available for this paper.

• Publication year

  2011

• Venue

  The Medical clinics of North America

• Publication date

  2011-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.mcna.2011.03.012PMID 21679791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Azithromycin for acute lower respiratory tract infections.

  2015cited by this paper
• Clarithromycin

  2012cited by this paper
• Tigecycline

  2012cited by this paper
• Review of Macrolides and Ketolides

  2012cited by this paper
• Clarithromycin

  2012cited by this paper
• Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany

  2011cited by this paper
• In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008.

  2010cited by this paper
• Sexually transmitted diseases treatment guidelines, 2010.

  2010cited by this paper
• In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

  2010cited by this paper
• A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.

  2010cited by this paper
• Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial.

  2010cited by this paper
• Helicobacter pylori infection.

  2009cited by this paper
• Increase in Pneumococcus Macrolide Resistance, United States

  2009cited by this paper
• Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.

  2009cited by this paper
• Telithromycin‐associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases

  2009cited by this paper
• A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline.

  2009cited by this paper
• Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and

  2009cited by this paper
• In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.

  2009cited by this paper
• Macrolide‐Induced Digoxin Toxicity: A Population‐Based Study

  2009cited by this paper
• Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

  2008cited by this paper
• Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.

  2008cited by this paper
• Azithromycin vs. benzathine penicillin G for early syphilis: a meta-analysis of randomized clinical trials

  2008cited by this paper
• Tigecycline for the Treatment of Acinetobacter Infections: A Case Series

  2008cited by this paper
• Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin–clavulanate in the treatment of acute bacterial sinusitis*

  2008cited by this paper
• Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.

  2008cited by this paper
• Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.

  2008cited by this paper
• Azithromycin for acute lower respiratory tract infections.

  2008cited by this paper
• Evaluation of a Potential Tigecycline‐Warfarin Drug Interaction

  2008cited by this paper
• Efficacy and Safety of Azithromycin 1 g Once Daily for 3 Days in the Treatment of Community-Acquired Pneumonia: an Open-Label Randomised Comparison with Amoxicillin-Clavulanate 875/125 mg Twice Daily for 7 Days

  2008cited by this paper
• Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment

  2008cited by this paper
• Acute pancreatitis related to tigecycline: Case report and review of the literature

  2008cited by this paper
• Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.

  2008cited by this paper
• A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

  2008cited by this paper
• Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.

  2008cited by this paper
• Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.

  2008cited by this paper
• Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

  2008cited by this paper
• Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii

  2007cited by this paper
• Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication

  2007cited by this paper
• Clinical Pharmacokinetics and Gastrointestinal Tolerability of a Novel Extended-Release Microsphere Formulation of Azithromycin

  2007cited by this paper
• The FDA and the case of Ketek.

  2007cited by this paper
• Tigecycline: A Novel Broad-Spectrum Antimicrobial

  2007cited by this paper
• Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy.

  2007cited by this paper
• Role for 5‑day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis

  2007cited by this paper
• American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

  2007cited by this paper
• Telithromycin Resistance in Streptococcus pneumoniae Is Conferred by a Deletion in the Leader Sequence of erm(B) That Increases rRNA Methylation

  2007cited by this paper
• The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis

  2007cited by this paper
• Metabolism, Excretion, and Pharmacokinetics of [14C]Tigecycline, a First-In-Class Glycylcycline Antibiotic, after Intravenous Infusion to Healthy Male Subjects

  2007cited by this paper
• Absence of an Interaction Between Tigecycline and Digoxin in Healthy Men

  2007cited by this paper
• Community‐acquired Pneumonia in North American Emergency Departments: Drug Resistance and Treatment Success with Clarithromycin

  2007cited by this paper
• Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.

  2007cited by this paper
• Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

  2007cited by this paper
• Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.

  2007cited by this paper
• Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo-β-Lactamase-Producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program

  2007cited by this paper
• Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials.

  2007cited by this paper
• An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

  2007cited by this paper
• National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study

  2007cited by this paper
• Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen

  2006cited by this paper
• Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment

  2006cited by this paper
• Comparison of In Vitro Activities of Tigecycline with Other Antimicrobial Agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan

  2006cited by this paper
• Brief Communication: Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature Review

  2006cited by this paper
• Streptococcus pneumoniae Isolates Resistant to Telithromycin

  2006cited by this paper
• Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease.

  2006cited by this paper
• Telithromycin-Nonsusceptible Clinical Isolates of Streptococcus pneumoniae from Europe

  2006cited by this paper
• Prevalence and Antibacterial Susceptibility of mef(A)-Positive Macrolide-Resistant Streptococcus pneumoniae over 4 Years (2000 to 2004) of the PROTEKT US Study

  2006cited by this paper
• Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

  2006cited by this paper
• Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.

  2006cited by this paper
• 2‐Week Triple Therapy for Helicobacter pylori Infection is Better Than 1‐Week in Clinical Practice: a Large Prospective Single‐Center Randomized Study

  2006cited by this paper
• Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003

  2005cited by this paper
• The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

  2005cited by this paper
• Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.

  2005cited by this paper
• Large Dosage Amoxicillin/Clavulanate, Compared With Azithromycin, for the Treatment of Bacterial Acute Otitis Media in Children

  2005cited by this paper
• A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

  2005cited by this paper
• Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

  2005cited by this paper
• Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam

  2005cited by this paper
• Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults.

  2005cited by this paper
• Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy Subjects

  2005cited by this paper
• Novel, Single-Dose Microsphere Formulation of Azithromycin versus 7-Day Levofloxacin Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults

  2005cited by this paper
• The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

  2005cited by this paper
• Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous Administrations

  2005cited by this paper
• Once-Daily Azithromycin for 3 Days Compared with Clarithromycin for 10 Days for Acute Exacerbation of Chronic Bronchitis

  2005cited by this paper
• Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization.

  2005cited by this paper
• Efficacy and Safety of a Novel, Single-dose Azithromycin Microsphere Formulation Versus 10 Days of Levofloxacin for the Treatment of Acute Bacterial Sinusitis in Adults

  2005cited by this paper
• Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone

  2005cited by this paper
• Efficacy of Telithromycin in Community-Acquired Pneumonia Caused by Pneumococci with Reduced Susceptibility to Penicillin and/or Erythromycin

  2005cited by this paper
• A Randomized, Multicenter, Double Blind, Double Dummy Trial of Single Dose Azithromycin Versus High Dose Amoxicillin for Treatment of Uncomplicated Acute Otitis Media

  2005cited by this paper
• Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.

  2005cited by this paper
• Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis.

  2005cited by this paper
• Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study

  2005cited by this paper
• A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study.

  2005cited by this paper
• Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis.

  2005cited by this paper
• Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.

  2005cited by this paper
• The pharmacokinetic and pharmacodynamic profile of tigecycline.

  2005cited by this paper
• Impact of Clarithromycin Resistance on Eradication of Helicobacter pylori in Infected Adults

  2005cited by this paper
• Efficacy and Safety of Oral Telithromycin Once Daily for 5 Days Versus Moxifloxacin Once Daily for 10 Days in the Treatment of Acute Bacterial Rhinosinusitis

  2004cited by this paper
• Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.

  2004cited by this paper
• A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia.

  2004cited by this paper
• Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.

  2004cited by this paper
• Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.

  2004cited by this paper
• Antimicrobial Resistance Incidence and Risk Factors among Helicobacter pylori–Infected Persons, United States

  2004cited by this paper
• Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults.

  2004cited by this paper

• Development of antibiotic dry powder inhalers formulations for the treatment of respiratory bacterial infections: A comprehensive review

  2026cites this paper
• Circadian considerations in antimicrobials

  2026cites this paper
• Investigation of the Binding of the Macrolide Antibiotic Telithromycin to Human Serum Albumin by NMR Spectroscopy

  2025cites this paper
• MACROLIDES IN VETERINARY MEDICINE. A REVIEW

  2025cites this paper
• Quality of different brands of clarithromycin tablets marketed in Ethiopia; implications for the future

  2025cites this paper
• Plasma concentration of azithromycin and correlation with clinical outcomes in patients with enteric fever

  2025cites this paper
• Treatment for non-tuberculous mycobacteria: challenges and prospects

  2024cites this paper
• Progress in approved drugs from natural product resources.

  2024cites this paper
• Common Pathophysiological Mechanisms and Treatment of Diabetic Gastroparesis

  2024cites this paper
• The Crisis of Macrolide Resistance in Pneumococci in Latin America

  2024cites this paper
• Molecular spectroscopy, solvent effect, and DFT studies of azithromycin solvate.

  2024cites this paper
• Voltammetric sensor based on a composite of chitosan, graphitized carbon black and polyarylenephthalide with molecular imprints for the determination of clarithromycin

  2024cites this paper
• pH and time effectiveness on azithromycin drug: A spectrophotometric approach

  2024cites this paper
• A Voltammetric Sensor Based on a Chitosan, Graphitized Carbon Black, and Molecularly Imprinted Polyarylene Phthalide Composite for Clarithromycin Detection

  2024cites this paper
• Develop adult extrapolation to pediatrics and pediatric dose optimization based on the physiological pharmacokinetic model of azithromycin

  2023cites this paper
• Antimicrobial Resistance in Bacteria from Meat and Meat Products: A One Health Perspective

  2023cites this paper
• Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?

  2023cites this paper
• Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody–induced skin toxicities in real-world metastatic colorectal cancer treatment

  2023cites this paper
• Side effects of antibiotics and perturbations of mitochondria functions.

  2023cites this paper
• Therapeutic potential of marine macrolides: An overview from 1990 to 2022.

  2022cites this paper
• Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice

  2022cites this paper
• Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine

  2022cites this paper
• Do antibiotics cause mitochondrial and immune cell dysfunction? A literature review.

  2022cites this paper
• Actinomycetes in Medical and Pharmaceutical Industries

  2021cites this paper
• Erythromycin versus azithromycin for treatment of preterm prelabor rupture of membranes: A systematic review and meta-analysis.

  2021cites this paper
• Discovery and Development of Antibacterial Agents: Fortuitous and Designed.

  2021cites this paper
• Anti-bacterial Agents

  2021cites this paper
• Principles of Appropriate Antimicrobial Therapy and Antibacterial Agents for Pediatric Ear, Nose, and Throat Infections

  2021cites this paper
• The drug discovery process: From ancient times to the present day

  2021cites this paper
• Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer

  2021cites this paper
• Nontuberculous Mycobacteria

  2021cites this paper
• Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations.

  2021cites this paper
• Discovery of Macrolide Antibiotics Effective against Multi-Drug Resistant Gram-Negative Pathogens.

  2021cites this paper
• Azithromycin-loaded linolenic acid-modified methoxy poly(ethylene glycol) micelles for bacterial infection treatment

  2021cites this paper
• Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections

  2021cites this paper
• Anti-cryptococcal activity of preussolides A and B, phosphoethanolamine-substituted 24-membered macrolides, and leptosin C from coprophilous isolates of Preussia typharum

  2021cites this paper
• Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

  2021cites this paper
• A genome-wide analysis of targets of macrolide antibiotics in mammalian cells

  2020cites this paper
• Pharmacogenomics of Antibiotics

  2020cites this paper
• MACROLIDE ANTIBIOTICS: A REVIEW

  2020cites this paper
• Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease

  2020cites this paper
• Macrocyclic sulfone derivatives: Synthesis, characterization, in vitro biological evaluation and molecular docking

  2020cites this paper
• Comparative Study of the Effect of Macrolide Antibiotics Erythromycin, Clarithromycin, and Azithromycin on the ERG1 Gene Expression in H9c2 Cardiomyoblast Cells

  2020cites this paper
• Gamitromisin ve Tulatromisinin Sığır Trakea Düz Kası Üzerine Etkileri

  2020cites this paper
• Evidence of Clinically Meaningful Drug–Drug Interaction With Concomitant Use of Colchicine and Clarithromycin

  2020cites this paper
• Evaluation of Mutations in 23S rRNA, rdxA and frxA Genes of Helicobacter pylori in Paraffin-Embedded Gastric Biopsy Specimens from Iranian Gastric Cancer and Gastritis Patients

  2020cites this paper
• ISOLATION AND IDENTIFICATION OF BACTERIAL SPECIES ASSOCIATED WITH ODONTOGENIC INFECTIONS

  2020cites this paper
• In vitro activities of telithromycin against Staphylococcus aureus biofilms compared with azithromycin, clindamycin, vancomycin and daptomycin.

  2020cites this paper
• Biodegradation of antibiotics: the new resistance determinants - part I.

  2020cites this paper
• Biodegradation of antibiotics: the new resistance determinants - part II.

  2020cites this paper
• The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance

  2020cites this paper
• Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis

  2019cites this paper
• Antibacterial activities of a series of novel 5-O-(4′, 6′-O-dimodified)-mycaminose 14-membered ketolides

  2019cites this paper
• Occurrence and distribution of trace levels of antibiotics in surface waters and soils driven by non-point source pollution and anthropogenic pressure.

  2019cites this paper
• Marine Macrolides with Antibacterial and/or Antifungal Activity

  2019cites this paper
• Cytotoxic comparison of macrolide antibiotics and their chlorinated disinfection byproduct mixtures.

  2019cites this paper
• Antibiotic Consideration in Transplant Recipients

  2019cites this paper
• In vitro synergistic activity of erythromycin and nisin against clinical Group B Streptococcus isolates

  2019cites this paper
• The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies

  2019cites this paper
• 14- and 15-membered lactone macrolides and their analogues and hybrids: structure, molecular mechanism of action and biological activity.

  2019cites this paper
• PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and Mycobacterium abscessus.

  2019cites this paper
• TCRM_A_214938 921..936

  2019cites this paper
• HEPATOPROTECTIVЕ EFFECT OF THE THOROUGHWAX EXTRACT IN EXPERIMENTAL TETRACYCLINE-INDUCED HEPATITIS

  2019cites this paper
• The clinical significance of statins-macrolides interaction: comprehensive review of in vivo

  2019cites this paper
• Mycobacterium avium Complex Disease

  2018cites this paper
• Nontuberculous Mycobacteria in Cystic Fibrosis

  2018cites this paper
• Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter

  2018cites this paper
• Management of lower respiratory tract infection in outpatient settings: Focus on clarithromycin

  2018cites this paper
• PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics

  2017cites this paper
• Perspectives on antibiotic treatment of NTM pulmonary disease

  2017cites this paper
• Chalcomycins from Marine-Derived Streptomyces sp. and Their Antimicrobial Activities

  2017cites this paper
• Mycobacterium avium Complex Disease

  2017cites this paper
• In-vitro study of quality control parameters of three different brands of azithromycin tablets

  2017cites this paper
• Pharmacokinetic and pharmacodynamic integration and modeling of acetylkitasamycin in swine for Clostridium perfringens

  2017cites this paper
• Role of Clarithromycin in Acute Exacerbations of Chronic Obstructive Pulmonary Disease.

  2017cites this paper
• Combination therapy with ampicillin and azithromycin improved outcomes in a mouse model of group B streptococcal sepsis

  2017cites this paper
• Diversity-oriented synthesis and cytotoxic activity evaluation of biaryl-containing macrocycles.

  2017cites this paper
• Pharmacodynamics of Macrolides, Azalides, and Ketolides

  2016cites this paper
• Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease

  2016cites this paper
• Antibiotic treatment for the sexual partners of women with bacterial vaginosis.

  2016cites this paper
• An efficient method to synthesize novel 5-O-(6′-modified)-mycaminose 14-membered ketolides

  2016cites this paper
• Chapter 2 – The Drug Discovery Process: From Ancient Times to the Present Day

  2015cites this paper
• Construction of a Novel Carbon Paste Clarithromycin Sensor for Low Level Concentration Measurement, Applications to Pharmaceutical and Biological Analysis

  2015cites this paper
• The Drug Discovery Process

  2015cites this paper
• The role of the immune response in the effectiveness of antibiotic treatment for antibiotic susceptible and antibiotic resistant bacteria

  2015cites this paper
• Advanced systolic heart failure and Mycobacterium avium complex (MAC) infection: Proposed immunologic mechanism, diagnostic dilemma and treatment considerations

  2015cites this paper
• A comprehensive review of glycosylated bacterial natural products.

  2015cites this paper
• Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections

  2015cites this paper
• Structural and Functional Implications of the Interaction between Macrolide Antibiotics and Bile Acids

  2015cites this paper
• Use and safety of azithromycin in neonates: a systematic review

  2015cites this paper
• Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent

  2015cites this paper
• Time-kill kinetics of antibiotics active against rapidly growing mycobacteria.

  2015cites this paper
• pneumoniae Infections in Illinois in 2012 Cluster of Macrolide-Resistant Mycoplasma

  2014cites this paper
• Enantioselective synthesis in carbohydrate-based drug discovery: imino sugars, alkaloids and macrolide antibiotics.

  2014cites this paper
• Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs.

  2014cites this paper
• Human Saliva-Based Quantitative Monitoring of Clarithromycin by Flow Injection Chemiluminescence Analysis: A Pharmacokinetic Study

  2014cites this paper
• Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment.

  2013cites this paper
• Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in broiler chickens.

  2013cites this paper
• Liposomal clarithromycin delivery for the treatment of pseudomonal lung infection in cystic fibrosis.

  2013cites this paper
• Macrocyclic Drugs and Synthetic Methodologies toward Macrocycles

  2013cites this paper